Management will host a conference call and live webcast at 8:30 AM ET to discuss the quarterly performance. Interested parties can join the call by dialing 1-866-744-5399 from the United States or +972-3-918-0644 for international access. A replay of the proceedings will remain available on the company’s investor relations website following the event.

Currently, Compugen is advancing several clinical-stage assets, including the anti-PVRIG antibody COM701, which is being studied in the MAIA-ovarian trial. The firm also maintains active partnerships with AstraZeneca for the development of rilvegostomig and with Gilead for the IL-18 blocker GS-0321. These collaborations utilize the company’s proprietary Unigen AI/ML platform to identify and validate novel cancer immunotherapy targets.